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Negative pressure wound therapy with instillation
(NPWTi): Current status, recommendations and
perspectives in the context of modern wound
therapy.
Adam Bobkiewicz, Adam Studniarek, Michał Drews, Tomasz Banasiewicz
REVIEW
Abstract—Introduction of negative pressure wound therapy
(NPWT) revolutionized the conception of wound healing. Cur-
rently, increasing number of studies confirmed the high efficiency
of this therapy in many clinical scenarios. Moreover, some
innovations have been introduced in recent years to improve
the management of complex and chronic wounds. NPWT with
instillation (NPWTi) combines traditional NPWT with applica-
tion of topical irrigation solutions within the bed of the wound.
Bioburden reduction, decreases time to wound closure, promotes
granulation and tissue formation. Fewer operative visits are
required when using NPWTi compared to standard NPWT.
However, there are still questioned aspects of the NPWTi and thus
its superiority over standard NPWT has not been fully indicated.
Moreover, based on current studies no firm conclusions have
been taken concerning the type of instilled solution preferably
used, range of dwell- time phase, range of negative pressure
and others. The main goal of the publication is to overview
and summarize the current state of art concerning NPWTi.
Moreover, mechanisms of action, review of the most commonly
used instilled solutions are discussed and clinical evidence of
NPWTi are described.
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I. INTRODUCTION
THE introduction of negative pressure wound therapy(NPWT) in the late 1980s simultaneously in the United
States and Germany revolutionized the management of com-
plex and chronic wounds.1–3
Its initial clinical indication was designed for chronic
wounds of lower extremity such as leg ulcers, decubitus ulcers
and traumatic wounds after open fractures. Very quickly the
indication for NPWT was extended to other varying wounds
with different underlying pathologies.
Because of excellent results of NPWT and the progress in
both basic science research and clinical trials regarding NPWT,
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this therapy has become a widely accepted and common
therapeutic modality. Currently, there is a wide spectrum of
indications for NPWT including open fractures, amputation
wounds, sternal wound infections, enterocutaneous fistulas,
open abdomen management, abdominal wound dehiscence,
vascular bypass site infection and many others.4–6
In 2003, Kinetic Concept Inc. introduced a first commer-
cialized system of NPWT instillation (NPWTi): V.A.C Instill
Wound Therapy. A new method of negative pressure wound
therapy combined the benefits of standard NPWT with an in-
troduction of incorporated, controlled and periodic instillation
of topical solution to the wound bed. The mechanism of action
allows for the delivery of instilled fluid to the bed wound
facilitating a removal of cellular debris, exudate and inflamma-
tory molecules that may impair the processes of proper wound
healing. Moreover, NPWTi decreases the bacterial bioburden
within the wound and influences the reduction of biofilm
formation.
Nowadays, NPWTi has been commonly applied to numer-
ous clinical scenarios. In 2013, following an expert panelists’
discussion, the first International Consensus Guidelines was
created to establish the principles for NPWTi.7 Although some
recommendations and guidelines have been reported before,
there are still number of questions concerning NPWTi. Ad-
ditionally, there is an increased list of publications regarding
NPWTi including different type of instilled solutions, setting
parameters such as instillation time, dwell time as well as time
of NPWT. Therefore, there is a constant debate in regards to
the most accurate recommendations.
The majority of publications concerning NPWTi are expert
opinions, case reports or case series therefore it is difficult to
establish evidence-based conclusions.
In this review, we focused on the current state of art
regarding NPWTi: present indications, types of administered
instilled solutions and potential problems with the utility of
NPWTi were highlighted. We analyzed other instilled solutions
used in NPWTi that were previously evaluated by other au-
thors and are currently not firmly recommended. Additionally,
we described the mechanisms of action for the purpose of
highlighting the principles of NPWTi and thus showing the
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potential superiority to the standard NPWT.
We believe that the presented detailed review may help
in optimal selection for NPWTi settings for specific clinical
indications and scenarios. Moreover, we hope this work may
increase researchers’ knowledge and improve the quality of
designed experimental studies regarding ongoing research in
the field of NPWTi.
II. MECHANISM OF ACTION
The mechanism of action for NPWTi remains the same in
regards to the standard NPWT and is the basis for successful
outcomes of NPWTi. The applied negative pressure within
the surgical wound indicates its multi-dimensional action that
positively influences the wound healing process.
The increase of local blood flow influences an enhanced
collagen synthesis and promotes mechanisms that stimulate
angiogenesis. NPWTi also leads to a decreased local tissue
edema, lowers the number of bacteria within the wound
and removes inhibitory agents. The use of NPWT positively
affects tissue granulation process and maintains a moist wound
environment. Additionally, NPWT reduces lateral tension of
the wound edge, positively influences the wound contraction
and supports a proper wound edge vascularity.8–10
III. CELLULAR AND MOLECULAR CHANGES
Both in vitro and in vivo models showed, that the ad-
ministration of reticulated open-cell foam (ROCF) generates
microstrain at the cellular level which has a direct influence
on the elevation of proliferating cells within the wound and
enhances vascularity.11, 12
At the cellular level, a mechanical strain generated with neg-
ative pressure stimulates sensory cells to molecular changes
within cells.13 Gravity and hemodynamic forces, as con-
stituents of NPWT, significantly influence the improvement
in microenvironmental conditions of the wound bed resulting
in an enhanced wound healing.14 Although, some mechanisms
of action at the cellular level are still unknown, the conception
of cellular mechanotransduction seems to accurately describe
the mechanisms of alteration and enhancement of cellular
properties with the usage of NPWT through the direct use
of administered negative pressure.15
In vitro studies demonstrated that the administration of
negative pressure wound therapy positively influences the
function and activity of fibroblasts.11 The use of NPWT
stimulates proliferation, production and remodeling of fi-
broblasts, extracellular matrix, as well as increases growth
factors production.11, 16 The results of in vitro studies were
confirmed by in vivo results. Scherer et al. confirmed that cell
proliferation expressed as a percentage of Ki67-positive nuclei
was significantly greater in NPWT group compared to other
groups in mice model.11
IV. BIOFILM
It has been presented that NPWTi significantly influences
the reduction of biofilm composed of varying microorganisms
within the wound, which is considered one of the main reasons
for impaired wound healing.
Based on research studies with an animal model and clinical
practice, it was stated that the presence of microorganisms
within the wound, their influence on the wound bed, quick
replication and tendency to form colonies result in biofilm
formation. Bacteria is the most common reason for biofilm
formation, however usually within a wound there is a complex
biofilm formation by bacteria, fungi and protozoa embedded
in a self-produced extracellular matrix of polysaccharides or
other extracellular polymeric substance (EPS), cellular debris
and exudates.17
Consequently, providing a substance to the wound, should
by definition remove not only the exudates and cellular debris
but also influence the destruction and removal of biofilm
bacteria which is a basis for its success.
Mechanical debridement, reduction of biofilm and autolytic
mechanisms are considered the most important components
of NPWTi action and they are key elements emphasizing the
advantage of NPWTi over the standard NPWT.18
The above-mentioned concept and the need for modification
of systems and treatment therapy of chronic wounds are
associated with the current state of the art, indicating that
microbial biofilm is one of the crucial factors impairing
wound healing.19–21 Phillips et al. analyzed based on an
animal model various antimicrobial solutions on Pseudomonas
aeruginosa biofilm.22 Using seven solutions with periodic
NPWT instillation, they compare their efficacy versus NPWT
alone and NPWT with saline solution. Using NPWT alone
(no instillation used), there was no statistical significance
in comparison to the untreated control group even though
the reduction in total CFUs was observed. All experimental
groups using both antimicrobial solutions and saline showed
statistical significance in the reduction of CFUs compared
to the untreated group. However, in authors’ opinion, in the
saline group the reduction in CFUs was rather associated with
mechanical removal than other potential mechanisms acting on
the bacteria’s biofilm. Comparing the antimicrobial solution
groups with the saline groups, all of them except one (S-
solution) showed statistical significance in reduction of CFUs.
Conventionally used lavage, which was initially considered
an important element of wound cleansing, has an increased
risk of bacteria dispersion within the wound bed as well as
beyond the wound. Allen et al. based on the wound models
compared the standard lavage technique and NPWTi and its
influence on the degree of bacterial dispersion and cross-
contamination using ex-vivo model with fluorescent bacterial
particles inoculation.23 Both low-pressure lavage and NPWTi
showed comparable effectiveness of wound cleansing (debris
reduction >90%). However comparing tissue damage, based
on three-dimensional photography, more severe tissue damage
was revealed in NPWTi treatment group (P <0.05). The most
important is the fact of no evidence for cross-contamination in
NPWTi. Gabriel et al. comparing bacterial bioburden reduction
in NPWTi group and the control group (standard wound-care
therapy) showed statistical significance in the time required to
decrease bacterial bioburden ( 6.0±1.5 versus 25.9±6.6 days
respectively).18
It is important to note that regardless of the type of the
negative pressure therapy, settings, type of instilled fluid, the
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crucial aspect is initial debridement of the wound. Appropriate
debridement is necessary to eliminate poorly vitalized and
necrotic tissue, all foreign bodies within the wound bed as well
as any excessive cellular debris. Currently, there are numerous
methods for debridement including lavage, autolytic agents,
ultrasound, chemicals and enzymes or surgical procedures.24
Regular debridement also plays an important role in bacterial
biofilm reduction.25, 26
V. TISSUE GRANULATION
Leung et al. comparing the standard NPWT versus NPWTi
analyzed the acceleration of wound granulation in porcine
model. Using the NPWT with instillation and normal saline in
4 cycles of instillation per day (dwell times: 5 or 60 minutes),
they demonstrated statistically significant wound filling and
collagen deposition within the granulated tissue within a bed
wound.27 Brinkert et al. in a prospective study evaluated the
effect of NPWTi used in different clinical scenarios.28 A total
of 131 patients were enrolled to either NPWTi group as the pri-
mary method of treatment (n=85; 64,9%) or received NPWTi
after a failed standard NPWT therapy (n=46; 35,1%). Granu-
lation of the wound bed was increased in NPWTi group versus
standard NPWT. Moreover, significant reduction of wound
volume was also shown in NPWTi versus standard NPWT.
Dead space of the wound as well as any undermined cavities
were granulated more rapidly in NPWTi in comparison to
the standard NPWT. Lessing et al. investigated the influence
of different application of standard NPWT and NPWTi on
granulation of the wound in porcine model.29 NPWTi with
saline ( 5 minutes of dwell time every 2,5 hours, negative
pressure -125 mmHg) and various settings of standard NPWT
(intermittent, continuous, dynamic) were applied on dorsal
excisional wound for 7 days. At the time of end point, tissue
samples were taken for histological examination. In NPWTi
group granulation thickness (p<0,05), greater reduction of
wound volume (p<0,05) and higher filling rate of the wound
(p<0,05) were statistically significant compared to the standard
NPWT.
VI. WOUND DRESSINGS
The proper application and arrangement of negative pressure
within the wound dressing is guaranteed with the use of
reticulated open-cell foam (ROCF). The most commonly used
foams on the market are: ROCF- G (V.A.C. R© GranuFoamTM
Dressing, KCI USA, Inc, San Antonio, TX) oraz ROCF-V
(V.A.C. VeraFlo CleanseTM Dressing System, KCI USA, Inc.).
Although pore sizes are comparable in both types of dressings,
the different chemical composition of dressings leads to the
fact that physical and chemical properties are different in both
cases of wound dressings. Therefore, the interactions between
the dressing and a wound are also different. ROCF-G is com-
posed of polyether- based polyurethane foam, whereas ROCF-
V is made of polyester-based polyurethane foam. ROCF-V is
less hydrophobic than ROCF-G, which allows for an easier
adherence and distribution of instilled fluid within the wound.
It was confirmed that the less hydrophobic property of
ROCF dressing is, the more affinity of fluid adherence within
the dressing is observed.30 Moreover, it is easier to drain the in-
stilled fluid with wound exudate and cellular debris outside the
wound. The better susceptibility of ROCF-V for preserving the
fluid within the wound dressing also allows for a lower risk of
pooling the fluid beneath the dressing and outside the wound,
which may contribute to an incidence of a leak and unsealing
of the wound dressing.31 Scanning electron microscopy images
showed similar pore size and structure of both ROCF-G and
ROCF-V.32 Comparable results were presented by Lessing et
al.30 The mean value of pore size was estimated to be 400 µm
to 600 µm in both ROCF-G and ROCF-V. Lessing et al. using
scanning electron microscopy compared mechanical properties
of ROCF-G and ROCF-V regarding tension, compression and
tearing properties.30 Moreover, the properties of individual
foams were analyzed in both wet and dry conditions. Wet
ROCF-V showed statistically better properties under tensile
and tear condition than ROCF-G, in both wet and dry circum-
stances. Comparing fluid distribution, ROCF-V showed better
capabilities of accumulating fluid versus ROCF-G. Based on
histological analysis, ROCF-V showed increased granulation
within the wound in comparison to ROCF-G after 7 days of
NPWTi or NPWT alone (P < 0.05).
It is important to note that both dressings ROCF-V and
ROCF-G present characteristic to all polymers, a type of
plasticizing effect and hydrolytic degradation due to the in-
teraction with instilled fluid; however, ROCF-V has shown
weaker above-mentioned properties.30
VII. CONTINUOUS- VERSUS PERIODIC- INSTILLATION
Although NPWTi has been used worldwide in many clinical
scenarios, there are no firm conclusions and recommendations
regarding the optimal type of instillation or a range of dwell
time and amount of instilled fluid.
Rycerz et al. described a wound model for the purpose of
assessment of optimal fluid distribution within a wound based
on two different methods of fluid administration (stained with
methylene blue).33Using agar-based model, they studied the
impact of continuous- and periodic- instillation on two types
of designed wounds: 1) a simple wound and 2) a complex
tunneled wound. In the model using continuous instillation,
30 ml of fluid/ hour throughout 3,5h was administered using
the negative pressure of -125 mmHg. On the other hand,
in the model using periodic instillation, 75 ml of fluid in
a simple wound model and 120 ml of fluid in a complex
wound model were administered and held for 10 min and later
repeated (-125 mmHg was set up). Comparing the two types
of therapies, an isolated penetration of the fluid within the
wound bed in both simple and complex wound was observed in
continuous instillation, whereas a regular pattern of wound bed
staining was revealed in periodic instillation. Despite the fact
that in the above-mentioned study they demonstrated better
administration parameters of instillation in the case of peri-
odic instillation, according to some studies the efficiency of
continuous instillation was also proven. Independently Lessing
et al. and Scimeca et al. demonstrated the effectiveness of
continuous instillation even though both used different instilled
fluids: saline solution and doxycycline, respectively.30, 34
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Argenta and Morykwas presented the benefits resulting from
the use of intermittent therapy in standard NPWT, emphasizing
the better perfusion of both the wound tissue and surrounding
tissues.3, 35 The element of intermittent therapy in NPWTi is
unequivocally part of the administered therapy composed of
instilled phase with the following dwell time phase, and then
with a formation and maintenance of negative pressure. How-
ever, it seems that both the benefits of instilled solution and
the intermittent pauses of active negative pressure positively
influence the effects of treatment with NPWTi.
VIII. INSTILLATION SOLUTIONS
Based on recent International Consensus Guidelines from
2013, the following instillation solutions were approved as
efficient for the purpose of instillation: Lavasept R© (polyhex-
anide 0.04%), Prontosan R© (polyhexanide 0,1% with betaine)
and Microcyn/Dermacyn R© (hypochlorous acid solution).7 The
final consensus was established when more than 80% of expert
panelists agreed on the appropriate efficiency of analyzed
instillation solution.
However, there are some limitations to these agreements.
Firstly, the recommendations are based on a personal opin-
ion of twelve expert panelists’ agreement. Secondly, various
studies with different methodologies were included into the
consensus such as prospective, randomized, comparative and
controlled studies leading to a creation of a bias in the
recommendations.
Based on the same consensus other solutions were also
evaluated. Despite the fact that they did not meet the agreement
criteria, it was stated that other instillation solutions may
still be considered in particular clinical scenarios. However,
ongoing research and clinical trials are required to confirm its
efficiency.
Below, we present the most common instillation solutions
used in NPWTi. The mechanism of action of a particular
solution was briefly described. Additionally, we indicated their
potential disadvantages and described both preclinical and
clinical studies regarding the utility of instillation solutions.
The most common instilled solutions are summarized in Table
1.
A. Isotonic solutions
Leung et al. by comparing NPWT with normal saline
instillation versus standard NPWT in porcine model showed
a statistical significance in collagen deposition and tissue
granulation within the wound in the experimental group with
NPWTi.27 Kim et al. conducted a prospective randomized
study comparing NPWT instillation with normal saline and
antiseptic solution (0,1% polyhexanide plus 0,1% betaine).43
There was no statistical significance in any of the analyzed
parameters (a number of operative visits, a length of hospital
stay, a wound healing rate and a wound healing rate within
30-day follow-up) in comparison to two cohorts of patients.
However, the time to final surgical procedure was statistically
shorter in the normal saline group (p= 0,038). In authors’
opinion the effectiveness of normal saline utility in NPWTi
is comparable to this antiseptic solution.
Brinkert et al. showed a high rate of wound closure in
98% of patients using NPWTi with normal saline in case
series of 131 patients.28 However, this study has one impor-
tant limitation. Almost half of the patients (48,8%) received
standard NPWT prior to implementation of NPWTi. Thus the
firm conclusion suggesting NPWTi as a more efficient therapy
is questionable. Fluieraru et al. in a retrospective case series
study proved the efficiency of NPWTi with saline instillation
in patients who previously did not recover under the standard
therapy as well as in patients with chronic complex wound
with no previous NPWT treatment.44 In general, in 23 out
of 24 patients tissue granulation was achieved and surgical
wound closure was possible using either flaps or skin grafts
treatment. Phillips et al. and Davis et al. independently proved
in porcine model that the reduction of P. aeruginosa bacterial
bioburden is significantly lower using saline when compared
to 0.1% polyhexanide and 0.1% betaine solution.22, 45
B. Hypochlorite-based solutions
1) Dakin’s solution: The historical root for the utility of
Dakin’s solution goes back to the times of World War I.46
At the time of its development it was considered one of the
most efficient bactericidal agents for combat injuries.47 The
main component of Dakin’s solution is sodium hypochlorite.
Dakin’s solution is a slightly alkaline solution with the concen-
tration of sodium hypochlorite ranging from 0,125% - 0,5%.
0,5% Dakin’s solution is termed “full strength” and it is the
highest concentration of sodium hypochlorite which is well
tolerated by the skin without any side effects. Consequently,
0,25% Dakin’s solution is termed “half strength”, whereas
0,125% is known as “quarter strength”. Based on both in
vitro and in vivo studies the efficiency of 0,125% Dakin’s
solution was confirmed against S. aureus, P. aeruginosa, E. coli
and Enterococcus.48–51 The cost, availability and simplicity of
using Dakin’s solution makes it one of the most commonly
used bactericidal solutions.
One of the raised controversies about Dakin’s solution is
its potential cytotoxicity. Kozol et al. confirmed the decreased
viability and migration of neutrophils when Dakin’s solution
was used.52 Similar results were obtained independently by
Heggers et al. and Lineaweaver et al., who studied the effect
of Dakin’s solution on fibroblasts.51, 53 Both studies confirmed
the dose- dependent effect of cytotoxicity on fibroblasts.
Thus, the optimal concentration of Dakin’s solution should be
considered in respect to both: the bactericidal effect resulting
in reduction of bacterial bioburden and the risk of alteration
of the function of macrophages and leucocytes which are the
crucial molecules acting in the inflammatory phase of wound
healing.
2) Microcyn R©/ Dermacyn R©: Microcyn is a solution com-
posed of hypochlorous acid and sodium salt. Contained
hypochlorous acid is similar to the one naturally occurring
in humans. In in vitro model, Microcyn reduced the level of
P. aeruginosa, E. coli and S. aureus with a statistical signifi-
cance.54, 55 Microcyn R©/ Dermacyn R© creates a moist wound-
care therapy with the property of rehydration of the necrotic
tissue and promoting autolysis. Goretti et al. compared Der-
macyn and diluted povidone iodine in the management of
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Table I
THE MOST COMMON SOLUTIONS AND AGENTS USED IN NEGATIVE PRESSURE WOUND THERAPY WITH INSTILLATION
Solution class Study Solution/ Agent Advantages Disadvantages
Isotonic solutions Brinkert et al.,
2013,28
Saline Solution, Lactated
Ringer’s solution,
1/ availability and low costs 1/ No antimicrobial property
Fluieraru et al.,
2013
2/ No sensitization observed 2/ In some studies lower efficiency
compared to antiseptic solution
Hypochlorite-
based solutions
Goss et al,
201436
Dakin’s solution, 1/ Availability, simplicity and low costs 1/ potential cytotoxicity
Wolvos, 201337
DermacynTM, 1/ There are no known drug interactions
or contraindications
2/ Contained hypochlorous acid natu-
rally occurring in human
Microcyn R©
Biguanidines Kim et al.,
2014,38
Polyhexamethylene, 1/ High efficiency in varying type of
wounds
Lehner et al.
201139
Polyhexanide
(Lavasept R©),
2/ No sensitization/ interaction ob-
served
Polyhexanide plus Betaine
(Prontosan R©)
Silver nitrates Gabriel et al.,
200818
0,5% silver nitrate 1/ Broad- bactericidal spectrum 1/ Must be protected from light expo-
sure
2/ Variety of commercial dressings 2/ Potentially cytotoxic
3/ P. aeruginosa, Enterobacteriaceae or
Salmonella resistance wasreported
Antibiotics Fleischmann et
al., 199840
Neomycin, Gentamicin,
Tobramycin,
Recommended strictly according to
bacterial culture results
Wolvos, 200441 Vancomycin,
Polymyxin B, Bacitracin
Catatonic
solutions
Matiasek et al.
2014?
Octenidine Effective in No firm conclusions based on prospec-
tive studies
contaminated wounds with
multiresistant bacteria
Insulin Scimeca et al.,
201034
Insulin 1/ Recommended in wounds due to DM
2/ No influence on systemic glycemia
level
Anesthetic Wolvos, 200441 Lidocaine Reduction of pain No antimicrobial property
Povidone-iodine
solution
Chang 200642 Povidone-iodine 1/Availability and low costs 1/ contraindicated in patients with hy-
perthyroidism, dermatitis herpetiformis
Cadexomer iodine 2/ Rapid antimicrobial action 2/ Cytotoxicity and sensitization
3/ Tissue staining
postsurgical infected ulcers of the diabetic foot.56 Patients
treated with Dermacyn presented significantly shorter healing
time and a higher wound healing rate at 6 months. Landsman
et al. evaluated the effect of Microcyn in the treatment of
mildly infected diabetic foot ulcers.57 In comparison to the
oral levofloxacin treatment group, Microcyn showed higher
clinical success rate of treatment (p= 0,033).
C. Biguanidines
1) Lavasept R©/Prontosan R©: Both Lavasept R©/Prontosan R©
belong to the group of biguanides composed of polyhex-
amethylene biguanide. Additionally, Prontosan contains 0,1%
betaine which has a comparable mechanism of action to
surfactant, reducing the surface tension of a water solution
allowing for a better penetration into the wound and to the
bacterial biofilm.
Minnich et al. conducted an in vitro study using a so-
lution of 0.1% polyhexanide and 0.1% of betaine.58 The
reduction of 13 tested microorganisms was evaluated after
7, 14, and 28 days. Based on this study, the reduction of S.
epidermidis, P. aeruginosa, Serratia marcescens, C. albicans,
S. aureus, vancomycin-resistant E. faecalis, P. mirabilis, E.
coli, methicillin-resistant S. aureus, A. baumannii, E. cloacae,
and E. faecalis was observed confirming the efficiency of
0.1% polyhexanide and 0.1% of betaine for microorganisms
reduction. Romanelli et al. in a randomized controlled trial
investigated the effect of the utility of polihexanide and betaine
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solution in patients with venous leg ulcers.59 Using a portable
device measuring pH of the wound surface (which correlates
with the level of bacterial burden), the authors confirmed the
efficacy of polihexanide and betaine solution in reduction and
stability of wound pH level in comparison to the control group
(p< 0,05). Hübner et al. evaluated the efficacy of 0.02 and
0.04% polyhexanide (polyhexamethylene biguanide, PHMB)
against Pseudomonas aeruginosa SG81 biofilm in in vitro
studies.? Results achieved in the PHMB group was comparable
to 0.1% chlorhexidine digluconate (CHX) in regards to the
amount of biofilm and bacterial metabolism in biofilms formed
with Pseudomonas aeruginosa. Sibbald et al. conducted a
multicenter, prospective, randomized clinical trial comparing
the effectiveness of polyhexamethylene biguanide (PHMB)
foam dressing and non-antimicrobial foam in the treatment
of chronic wounds.60
Bacterial bioburden was significantly reduced in PHMB
foam group (P = 0,016). In addition, pain reduction was
revealed as a statistically significant result at 2 weeks and at
4 weeks of the therapy in the group of PHMB management.
Wound size in PHMB was also reduced in comparison to the
non- antimicrobial foam.
The efficiency of Lavasept R© was independently confirmed
in clinical practice by a number of authors. Lehner et al.,
described the utility of Lavasept R© in 23 patients with infected
hip endoprosthesis (19 defined as an early infection and 4 as a
late infection).39 The success rate was 84% in early infection,
whereas in late infection 50% of success was reported. Thus in
authors’ opinion, NPWTi with Lavasept may be considered as
a salvage management for infected endoprosthesis, especially
in the early course of an infected hip endoprosthesis.
Köster evaluated the effect of using NPWT with Lavasept
instillation in patients with an early periprosthetic infection
following a knee endoprosthesis placement.61 Only in one
patient the implant needed to be removed, whereas in the
majority of patients implant was preserved. NPWTi was con-
tinued from three to nine days. In all except one patient no
infection was present at the time of follow-up (between 12 and
34 months postoperatively) confirmed by clinical, radiological
and laboratory examination. In authors’ opinion NPWTi with
Lavasept reduces the number of surgical revisions, enhances
the wound healing and reduction of infection leaving the knee
implant in situ.
D. Silver nitrate
Silver nitrate possesses a potential property for a creation
of somehow impermeable barrier against microorganisms’
penetration in the bed wound.62 However, in in vitro models it
was observed that silver nitrate (but also nanocrystalline silver)
exhibited a cytotoxic effect to cells, therefore playing a key
role in the healing processes with the effect on leukocytes and
macrophages, as well as fibroblasts and keratinocytes.?, 53
In porcine model study presented by Wright et al., slightly
different results were observed.63 An increased apoptosis and
decreased level of matrix metalloproteinase may potentially
support the process of wound healing. The crucial element
making the difference between in vitro and in vivo studies
seems to have a potential to bind the ionic silver which
is different in organic and inorganic constituents. Gabriel et
al. did not observe any side effects of using silver nitrate
for wound healing in the fifteen patients that they analyzed.
Consequently, the instillation with silver nitrate was continued
until the time of confirmed clearance of bacterial bioburden
within the wound.18 Statistical significance was revealed com-
paring the association between bacterial bioburden and the rate
of wound closure in NPWTi group versus moist wound-care
therapy (p< 0,001).
E. Povidone-iodine solution
Povidone-iodine solution is a well- known disinfecting agent
commonly used in trauma and surgical wounds. Optimal
effectiveness of povidone-iodine solution was established with
1:100 dilution. However, solution with 1:10,000 dilution still
presents bactericidal activity.64, 65 Potential disadvantages of
povidone-iodine solution are tendency for an irritation to
the applied site, cytotoxicity and staining of the tissues.
Although in some in-vivo and animal studies the cytotoxicity
was observed, these results were not confirmed in humans.66
Povidone-iodine solution did not negatively influence bed
wound healing.67, 68 Additionally, in comparison to other anti-
infective agents (e.g. neomycin), the sensitization rate of
povidone-iodine is relatively low.69 Chang et al. confirmed
the efficiency of povidone-iodine solution in spinal surgery
indicating a higher surgical site infection rate in the control
group (P<0,05).42
F. Insulin
The potential positive effect of topical application of in-
sulin on wound healing has been reported in basic science
research. However, there are not many studies on insulin
instillation in humans, therefore firm conclusions should not
be taken. In both rat and rabbit studies, the application of
insulin (or combined insulin-zinc therapy) promoted wound
healing.?, 70 Wilson et al. recommended the use of insulin
solution for complex and chronic wounds resulting from
diabetes mellitus including pressure ulcers and amputation site
stumps.71 Rezvani et al., investigated the use of topical in-
sulin on wound healing in randomized, double-blind, placebo-
controlled trial.72 The mean rate of wound healing was 46.09
mm2/day in the insulin treatment group and 32.24 mm2/day in
the control group (P = 0.029). It is important to note that the
symptoms of hypoglycemia resulting from the insulin therapy
were not observed in any of the patients. Similar results were
supported by Greenway et al. indicating that topical insulin
is an accelerator of wound healing in humans.73 Scimeca et
al. using NPWTi with insulin in a case report confirmed the
efficacy for the treatment of chronic wounds due to emergency
amputation at the midfoot level.34
IX. CLINICAL INDICATIONS
The review of recent publications concerning NPWTi are
summarized in Table 2.
In 1988, W. Fleischmann who is considered as a pioneer in
NPWT instillation and negative pressure therapy, published
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Table II
TABLE 2. RECENT STUDIES CONCERNING NEGATIVE PRESSURE WOUND THERAPY WITH INSTILLATION
Author and year Type of study Number
of
NPWTi
patients
Type of instilled fluid Instill
time
(sec)
Dwell
time
Instillation cycle
(hour)
Negative
pressure
Days of
NPWTi
(mmHg) mean (range)
Fleischmann et
al., 199840
Case series 27 Nebacetin (neomycin and
bacitracin) plus polyhex-
anidine
NA 30 min NA Od -50
do
33,5 (30-37)
-600
Gabriel et al.,
200818
Retrospective 15 Silver nitrate 30 1 sec Every 2 hour -125 9,8 (5-20)
Wolvos, 200441 Case series 5 1 or 2% Lidocaine + an-
tibiotic1
15-60 5 min Every 3 hour -125 15 (5-24)
Bernstein BH
and Tam H,
200574
Case series 5 Polymyxin (500.000 IU)
plus Bacitracin (50.000
IU) in 2L of saline
90 5 min Every 6 hour -125 NA
Brinkert et al.,
201328
Prospective 131 Saline 20 10 min Every 6 hour
(range: every
4-12 hour)
-125 12,19
Kim et al., 2015 Prospective,
randomized
100 Saline versus 0.1% Poly-
hexanide + 0,1% Betadine
NA 20 min Every 2 hour NA NA
43
Gabriel et al.,
201475
Retrospective 48 Saline or Prontosan R© NA 1-60 sec Every 2 hour -125 NA
Kim et al.,
201438
Retrospective 68 Prontosan R© NA 6 or 20
min
Every 2 or 3,5
hour
-125 NA
Goss et al.,
201436
Prospective 7 0,125% Dakin’s solution
(“quarter strength”)
NA 10 min Every 1 hour -125 7
Fluieraru et al.,
201344
Retrospective 24 Saline 30 10 min Every 4 hour -125 10,1 (6-15)
Wolvos, 201337 Case series 6 Microcyn or Dakin’s solu-
tion (“quarter strength”)
NA 5 or 10
min
Every 2 or 4 hour From
-100 to
-125
Jul 54
Lehner et al.
201139
Prospective,
multicenter
32 Lavasept R© (n=31), saline
(n=1)
<60 19 min
(5-30)
From 5 to 40 cy-
cles/day
From
-125 to
-200
16,3 (9-46)
Koster, 200961 Case series 10 Lavasept R© Okt 20 10-15
min
NA NA 03. Sep
Leffler et al.,
200976
Case series 6 Lavasept R© 20 20 min Every 4 hour -125 NA
an initial study concerning the influence of instilled fluid
on the wound treatment.40 Using NPWTi with antiseptic or
antibiotic solutions in 27 patients with acute and chronic
infections of bone and soft tissue as well as chronic os-
teomyelitis, they confirmed the efficiency of NPWTi in 26
patients with one recurrence of infection during 3-14 months
of follow-up. Gabriel et al. published a retrospective study
comparing patients treated with NPWTi and standard moist
wound care.18 The majority of patients were treated with
NPWTi due to pressure ulcers, extremity trauma (including
bone exposure) and abdominal surgical wounds. In the NPWTi
group of treatment the time of required treatment, wound
closure, resolution of wound infection and hospital stay were
significantly shorter in comparison to the standard method of
treatment (p< 0.001). Wolvos in his initial report of clinical
practice with NPWTi described a routine use of combined
Lidocaine and antibiotic solution for the purpose of chronic
and complex wound treatment.41 Surprisingly, all patients
reported a reduction in pain following NPWT instillation
with 1-2% Lidocaine as a topical anesthetic. Wolvos also
observed that an appropriate, targeted antibiotic (based on the
microbiological results) decreased the bacterial burden in the
wound. Bernstein and Tam described a case series of patients
with post-surgical diabetic foot wounds treated with NPWTi.74
Based on their initial experience, the application of topical
antibiotics positively influences the progress of wound healing
in chronic and complex wounds after surgical management in
DM patients. In authors’ opinion, NPWTi positively affects
the wound fluid viscosity, decreasing inflammatory agents and
cellular debris and it also reduces bacterial burden. Brinkert et
al. in a prospective study compared the efficiency of NPWTi
and standard NPWT in a group of 131 patients treated in
three referral orthopedic or surgical centers in France.28 The
most common clinical indication for both NPWTi and standard
NPWT was an open fracture (n=46), pressure ulcer (n=27) and
non-healing postoperative dehiscence (n=25). Wound closure
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was possible to be achieved in 98% of patients treated with
NPWTi with the mean duration of the therapy 12,19 days. In
the recent prospective randomized study, Kim et al. analyzed
the effect of NPWTi on wound healing using two different
solutions: normal saline versus antiseptic solution (0.1% poly-
hexanide plus 0,1% betaine).43 In the majority, chronic or
complex wound was located within the lower extremity in
both analyzed groups of treatment. There was no statistical
difference between the compared groups of treatment for
the number of surgeries, the length of hospital stay, wounds
closed/ covered ratio and wounds ratio that remained closed
within 30 days of follow up. The only significance was the
time to final surgical procedure which was favorable in NPWTi
with saline solution group (p=0,038). Based on this study,
normal saline and antiseptic solution (0.1% polyhexanide plus
0,1% betaine) demonstrate a similar efficacy. Gabriel et al.
compared the standard NPWT and NPWTi with saline or
polyhexanide in patients with extremity or trunk wounds.75
A total of 48 patients treated with NPWTi showed a statistical
significance in comparison to the standard NPWT for the time
of hospital stay (8,1vs 27,4 days), duration of the therapy (4,1
vs 20,9 days), time of wound closure (4,1 vs 20,9 days) and
mean operating room debridement (2,0 vs 4,4). Goss et al. in a
prospective pilot study evaluated the efficacy of the reduction
of a wound bacterial bioburden comparing the standard NPWT
and NPWTi.36 Dakin’s solution was used as an instilled bac-
tericidal agent. Chronic venous stasis and diabetic foot ulcer
were the most common underlying wound pathologies in both
treatment groups with the mean time of wound duration 30
months in the standard NPWT group and 23 months in NPWTi
group. At the time of end point (7th day of the therapy), there
was no statistically significant difference between these two
groups in reduction of bacterial bioburden (CFU/ gram of
tissue culture; p=0,43). However, the mean absolute reduction
of bacterial bioburden was statistically significant in NPWTi
group versus standard NPWT (p=0,016). Fluieraru et al. used
NPWTi as the primary method of treatment for extensive
undermining deep wounds (n=12) as well as in patients who
failed the standard NPWT (n=12).44 Isotonic saline was used
as an instilled fluid with a 10-minute dwell time and 30
seconds of instillation. There was no complication associated
with NPWTi. In 23 patients wound closure was achieved using
flaps or skin grafts following preconditioning of the wound bed
with the use of NPWTi. In all patients, good results of tissue
granulation and filling of the wound cavities were observed.
Recently, Wolvos published a small case series of pa-
tients treated with NPWTi in contaminated, chronic abdominal
wounds (n=3) or infected wounds within the lower extremity
(n=2) and chest wall (n=1).37 Wound healing and closure
were achieved in all patients using skin graft or surgical
closure (primary, secondary or delayed primary). There was no
difference in quality and the amount of tissue granulation in
patients treated with NPWTi (n=6) and standard NPWT (n=1),
even though both groups were small and inconsistent regarding
the types of the underlying pathologies of the wound and
the degree of the contamination, which is a limitation of the
study. In 2011 Lehner et al. published a multi-center prospec-
tive observational study concerning the utility of NPWTi in
patients following hip and knee replacements with surgical
site infection associated with orthopaedic implants.39 Clinical
indication for introduction of NPWTi included infected hip
implant (n=20), infected knee implant (n=10) and 2 patients
with infected osteosynthesis material. Routinely, polyhexanide
was used as an instilled fluid in all but one patient in whom
saline was used. Twenty-two patients had an acute infection
(<8 weeks after orthopedic implant placement), whereas ten
patients had a chronic infection (between 8 and 36 weeks
postoperatively). After NPWTi course, an eradication of the
wound infection was confirmed in 24 patients (75%), whereas
in 6 patients the recurrence of the wound infection was
revealed (18,8%) and in 2 patients ongoing wound infection
was reported. Koster presented ten patients with an implant-
associated infection following a knee implant placement.61
After a required wound debridement, NPWTi was initialized
using Lavasept R©. During the observational period of 13-34
months after a completed NPWTi therapy, only in one patient
there was a case of a reinfection. Similar results were achieved
by Schintler et al., who used NPWTi with Lavasept R© in
patients with soft tissue infections and necrotizing fasciitis.77
Additionally, in eight patients bone exposure or septic arthritis
were observed. The time of administration of NPWTi ranged
from 4 to 18 days. In all patients wound closure was achieved
using skin graft, flaps or secondary closure. Leffler et al.
described a small case series of 6 patients with osteomyelitis
within the lower extremity (n=5) or the upper extremity (n=1)
treated with NPWTi.76 Lavasept R© was used as an instilled
fluid with the following settings: 20 seconds of instillation
with 20-minute dwell time followed by NPWT at -125 mmHg.
After the NPWTi therapy, sterile bacterial cultures from the
site of an infection were confirmed in all patients. There
was no recurrence of a wound infection following a flap
reconstruction. Also, they did not observe a flap loss due to
the impairment of wound healing.
X. CONTRAINDICATIONS AND WARNINGS
Similarly to the standard NPWT, the list of indications for
NPWT with instillation has been recently increased. There has
been a tremendous progress in in the field of NPWT as well
as NPWT with instillation leading to the fact that this therapy
is currently used in many clinical scenarios.
However, there are some clinical situations when more
attention should be taken. Some solutions should also be
avoided as an instillation. Contraindications for NPWTi are
exactly the same as for standard NPWT and include: exposed
blood vessels or nerves, exposed bowels (or qualified for
abdominal NPWT) or anastomotic sites. Solutions containing
octenidine, hydrogen peroxide and other alcohol-based prod-
ucts are contraindicated in NPWT with instillation because
of their interactions and potential destructive effect on foam
dressings.? Certain contraindications are specific to the applied
solution. For example, neomycin may be absorbed locally and
an increased serum concentration may result in nephrotoxic
and ototoxic reactions.78 Anaphylaxis caused by the local
administration of Bacitracin or Polymyxin B or when used
as an irrigation was also reported.79–81 Although some authors
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reported shock, coma or even death related to povidone iodine
solution and hydrogen peroxide utility in surgical debridement,
generally both local antiseptics seem to be safe and generally
recommended for the purpose of wound cleansing.82, 83
Fluid instillation should not be delivered directly to the
abdominal or thoracic cavities.84 Firstly, a potential retention
within the human cavity may decrease the body temperature.
Secondly, instilled fluid may be retained within the body cav-
ities and may not be properly suctioned. Thus, the cases with
a present bacterial inflammation may lead to intra-abdominal/
intrathoracic abscesses formation, despite the proper mainte-
nance and application of negative pressure. However, D’Hondt
et al. recently described a case report of NPWTi use in a
patient treated with open abdomen management following
a pancreatic surgery.85 Due to a failure of previous ther-
apy (included abdominal NPWT), NPWT with gentamicin
and metronidazole (based on antibiogram results) was im-
plemented. Instillation time was set for 20 seconds with 10
minutes of dwell time and a negative pressure of -125 mmHg.
During the 12-day no local or systemic side effects of NPWTi
were observed and the eradication of B. fragilis, P. aeruginosa
and Lactobacillus was confirmed based on abdominal cultures.
It is important to note that described patient developed frozen
abdomen. Thus, possibly the retention of instilled fluid is min-
imized by the granulated tissue preventing it from pooling the
solution directly through the entire abdominal cavity. Based
on our experience, we agree with the authors that NPWTi
may serve as an important alternative when the standard open
abdomen therapy fails. However, further research and clinical
trials are required to evaluate the safety and efficiency of
NPWTi in open abdomen. Because of the above mentioned
reasons, NPWT with instillation should be avoided in clinical
situations with unexplored wound or a potential tunnel drained
into body cavities. NPWTi should not be placed over skin flaps
or grafts with a potential risk of failure and problems with
adapting and healing of the skin flaps or grafts.
XI. CONCLUSIONS
Based on current knowledge supported by clinical trials,
NPWTi is found as an important alternative to standard NPWT
in many clinical scenarios. Moreover, in some publications the
superiority of NPWTi over standard NPWT was highlighted.
Further studies regarding both basic science as well as
clinical trials are needed to establish the firm conclusions
concerning the efficiency of NPWTi.
From practical point of view, in authors’ opinion it is
important to share experience and collect data from varying
institutions in different clinical indications to create firm
conclusions and form guidelines for NPWTi.
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